Investigational Drug

An Investigational New Drug (IND) is a compound or biological substance that has demonstrated sufficient preclinical safety data to receive regulatory authorization from health authorities (such as the FDA) to be administered to human subjects in controlled clinical trials. It is not approved for general commercial sale or clinical prescription.

Many multi-receptor incretins (such as retatrutide, a triple GLP-1/GIP/glucagon agonist) are investigational drugs. They are actively evaluated in Phase 2 or 3 trials under strict safety protocols, but cannot legally be prescribed outside trials.

The investigational stage is where peptide hype concentrates. Trial results make headlines years before any approval decision, and unregulated sellers move in. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs and have not been found safe and effective for any condition. It has warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide.

Investigational status is permission to study a compound under controls, not a verdict that it works. An IND application must include animal pharmacology and toxicology data, manufacturing information and detailed clinical protocols, along with commitments to informed consent and ethics board review. The product used in a trial is made and tested to defined standards. A vial bought online under the same name has none of those safeguards.

Promising early results do not guarantee approval. Larger, longer trials can reveal side effects or weaker benefits that smaller studies missed, and many investigational drugs never reach the market. Until regulators have reviewed the full evidence, claims about an investigational peptide’s benefits and safety should be treated as provisional, however impressive the early numbers look.

“Investigational means almost approved”

An investigational drug has been allowed into human testing, which is a long way from approval. Phase 2 and phase 3 trials can still uncover safety problems or show that the benefit is smaller than hoped, and sponsors sometimes abandon programmes. Only a completed regulatory review establishes that a drug is safe and effective for a specific use.

“Buying a trial drug online is just early access”

Legitimate access outside a trial goes through FDA’s expanded access (compassionate use) pathway. It is meant for patients with serious or immediately life-threatening conditions who have no satisfactory alternative and cannot join a trial, and it involves a physician, the manufacturer and FDA. Grey-market products bearing a trial drug’s name are not that drug in any verified sense.

“Investigational and research chemical mean the same thing”

An investigational drug is being developed by a sponsor under an IND, with manufacturing controls, ethics oversight and safety reporting. “Research chemical” is a sales label with no regulatory review behind it. Some peptides sold this way have never been the subject of an active drug development programme in humans.

What is an investigational new drug (IND)?

In the United States, an IND is the application a sponsor submits to FDA to begin testing an unapproved drug in people. It contains preclinical safety data, manufacturing information and clinical protocols. After submission, the sponsor must wait 30 calendar days before starting trials, giving FDA time to check that participants will not face unreasonable risk.

Is retatrutide FDA approved?

As of FDA’s statement updated in October 2026, retatrutide had not been found safe and effective for any condition and could not be used in compounding under federal law. It is an investigational triple agonist of the GLP-1, GIP and glucagon receptors, studied in clinical trials such as the phase 2 obesity trial published in 2023.

Can I get an investigational drug outside a clinical trial?

Possibly, through FDA’s expanded access programme, sometimes called compassionate use. It may apply when a patient has a serious or immediately life-threatening condition, no comparable alternative exists, trial enrolment is not possible, and the potential benefit justifies the risk. A physician must make the request, and the manufacturer must agree to supply the drug.

What is the difference between an investigational drug and an approved drug?

An approved drug has completed clinical development and a regulatory review that judged its benefits to outweigh its risks for specific uses, with an approved label and ongoing safety monitoring. An investigational drug is still being studied, its benefits and risks are not yet established, and it may only be given within trials or authorised access programmes.